Chimerix, a biopharmaceutical company developing oral antiviral therapeutics for CMV, filed on Friday with the SEC to raise up to $85 million in an initial public offering. The Durham, NC-based company, which booked $34 million in revenue for the 12 months ended 12/31/2012, plans to list on the NASDAQ under the symbol CMRX. Morgan Stanley and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
